Pityriasis rubra pilaris (PRP) is a rare inflammatory papulosquamous skin disease that is often refractory to conventional therapies. The off-label use of biologics, such as anti–tumor necrosis factor, anti–interleukin (IL) 12/IL-23, and anti–IL-17 agents, has been proven successful in the past 2 decades for PRP treatment. Our aim was to analyse the literature for the use of biologics in PRP treatment. We conducted a review by performing PubMed and ClinicalTrials.gov searches. Sixty-eight articles met our selection criteria and are herein discussed. Out of 86 PRP patients, the vast majority were treated with anti–tumor necrosis factor, anti–IL-12/IL-23, or anti–IL-17 biologics, either alone or in combination therapy. A marked-to-complete response was observed in 50%-78%, a partial response in 11%-25%, and no or poor response in 11%-25%. This review has several limitations, including small sample sizes and the lack of shared study design criteria. In some instances, PRP might have resolved spontaneously. Further, the presence of concomitant therapy or the lack of detailed data on previous treatments, makes it difficult to strictly define a therapeutic role per se of specific biologics in PRP. This review shows that biologics may be regarded as a tool for PRP treatment alone or in combination therapy although clinical trials are needed to better assess their efficacy and safety.

毛发糠疹糠疹（PRP）是一种罕见的炎性丘疹性皮肤病，通常对传统疗法无能为力。在过去的20年中，已证明在生物标签外使用抗肿瘤坏死因子，抗白细胞介素（IL）12 / IL-23和抗IL-17药物是成功的。我们的目的是分析在PRP治疗中使用生物制剂的文献。我们通过执行PubMed和ClinicalTrials.gov搜索进行了审查。六十八篇文章符合我们的选择标准，在此进行讨论。在86名PRP患者中，绝大多数单独或联合接受抗肿瘤坏死因子，抗IL-12 / IL-23或抗IL-17生物制剂治疗。显着至完全缓解的比例为50％-78％，部分缓解的比例为11％-25％，无或较差的响应比例为11％-25％。该评价有一些局限性，包括样本量小和缺乏共同的研究设计标准。在某些情况下，PRP可能会自发解决。此外，伴随疗法的存在或先前治疗方法的详细数据的缺乏使得难以严格定义特定生物制剂本身在PRP中的治疗作用。这项综述表明，尽管需要进行临床试验以更好地评估其功效和安全性，但生物制剂可能被视为单独或联合治疗PRP的工具。因此很难严格定义PRP中特定生物制剂本身的治疗作用。这项综述表明，尽管需要进行临床试验以更好地评估其功效和安全性，但生物制剂可能被视为单独或联合治疗PRP的工具。因此很难严格定义PRP中特定生物制剂本身的治疗作用。这项审查表明，尽管需要进行临床试验以更好地评估其疗效和安全性，但生物制剂可能被视为单独或联合治疗PRP的工具。